Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $29.22 USD
Change Today -1.26 / -4.13%
Volume 1.6M
HZNP On Other Exchanges
Symbol
Exchange
Frankfurt
As of 8:10 PM 08/31/15 All times are local (Market data is delayed by at least 15 minutes).

horizon pharma plc (HZNP) Key Developments

Horizon Pharma plc Names George Hampton as Executive Vice President, Global Orphan Business Unit and International Operations

Horizon Pharma plc named George Hampton as executive vice president, global orphan business unit and international operations, reporting directly to Timothy P. Walbert, chairman, president and chief executive officer, effective immediately. Hampton has also joined the Horizon's Executive Committee. Hampton joined Horizon Pharma in 2008 as a consultant and full time as a group vice president, international operations in April 2015. Most recently, Hampton served as president and chief executive officer of a privately held technology company.

Horizon Pharma plc Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Provides Earnings Guidance for the Full Year 2015

Horizon Pharma plc reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported revenues were $172,821,000 compared to $66,062,000 a year ago. Operating loss was $33,173,000 compared to $7,100,000 a year ago. Loss before expense for income taxes was $128,866,000 compared to $26,889,000 a year ago. Net income was $31,814,000 or $0.20 diluted per share compared to net loss of $27,769,000 or $0.38 per basic and diluted per share a year ago. Net cash provided by operating activities was $41,584,000 compared to $16,761,000 a year ago. Purchase of property and equipment was $704,000 compared to $543,000 a year ago. Adjusted Non-GAAP net income was $61,898,000 compared to $19,766,000 a year ago. Diluted adjusted Non-GAAP earnings per share was $0.39 against $0.20 a year ago. Non-GAAP cash provided by operating activities was $129,595,000 compared to $20,130,000 a year ago. Adjusted operating cash flow in the second quarter of 2015 as $129.6 million. LBITDA was $69,821,000 compared to $14,457,000 a year ago. Adjusted EBITDA was $76,050,000 compared to $21,479,000 a year ago. For the six months, revenues were $285,962,000 compared to $117,988,000 a year ago. Operating loss was $28,409,000 compared to $5,513,000 a year ago. Loss before expense for income taxes was $146,506,000 compared to $234,244,000 a year ago. Net income was $12,261,000 or $0.08 diluted per share compared to $234,019,000 or $3.34 diluted per share a year ago. Net cash used in operating activities was $29,155,000 compared to net cash provided by operating activities of $16,004,000 a year ago. Purchase of property and equipment was $2,281,000 compared to $1,037,000 a year ago. Adjusted Non-GAAP net income was $86,405,000 compared to $26,804,000 a year ago. Diluted adjusted Non-GAAP earnings per share was $0.60 against $0.29 a year ago. LBITDA was $53,033,000 compared to $212,363,000 a year ago. Adjusted EBITDA was $86,405,000 compared to $26,804,000 a year ago. Non-GAAP cash provided by operating activities was $161,547,000 compared to $242,593,000 a year ago. For the full year 2015, the company expects net sales to be in the range of $660 to $680 million and Adjusted EBITDA to be in the range of $265 to $280 million.

Horizon Pharma Seeks Acquisitions

Horizon Pharma plc (NasdaqGS:HZNP) is seeking acquisitions. Paul Hoelscher, Chief Financial Officer, said, "We continue to be aggressive in our pursuit of M&A opportunities. To that end, as we've previously stated future acquisitions may impact these forecasted rates and we will update our guidance as appropriate when that happens."

Horizon Pharma plc Announces Collaboration with Fox Chase Cancer Center to Study ACTIMMUNE (interferon Gamma 1b) in Combination with PD-1/PD-L1 Inhibitors in Various Forms of Cancer

Horizon Pharma plc announced a collaboration with Fox Chase Cancer Center to study ACTIMMUNE (interferon gamma-1b) in combination with PD-1/PD-L1 inhibitors in various forms of cancer including advanced urothelial carcinoma (bladder cancer) and renal cell carcinoma. Preclinical cell line research has indicated that interferon gamma enhances cellular PD-L1 expression on endothelial cells (inner lining of the blood vessel) and on some tumor cells. By enhancing cellular PD-L1 expression on tumor cells, interferon gamma may promote or enhance the effect of the PD-1 or PD-L1 inhibitors. The first study being planned as part of the collaboration will be a dose-ranging study to determine a suitable dose for ACTIMMUNE with PD-1/PD-L1 inhibition. Once the ideal combination strategy is determined, the investigators intend to expand the study to include patients with metastatic bladder and renal cell carcinomas. Additional studies are expected to follow depending on initial results.

Horizon Pharma plc Provides Sales Guidance for the Second Quarter Ended June 30, 2015 and Revises Earnings Guidance for the Full-Year 2015

Horizon Pharma plc provided sales guidance for the second quarter ended June 30, 2015 and revised earnings guidance for the full-year 2015. For the second quarter of 2015, the company estimates net sales in the range of $170 million to $172 million. For the full year of 2015, the company now estimates net sales in the range of $660 million to $680 million against $590 million to $610 million expected earlier. The company now estimates adjusted EBITDA in the range of $265 million to $280 million against $235 million to $250 million expected earlier.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HZNP:US $29.22 USD -1.26

HZNP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Endo International PLC $77.00 USD -1.70
Pfizer Inc $32.22 USD -0.44
View Industry Companies
 

Industry Analysis

HZNP

Industry Average

Valuation HZNP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 9.9x
Price/Book 3.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 6.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HORIZON PHARMA PLC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.